{"id":"W3164457337","doi":"10.1136/annrheumdis-2021-eular.2000","title":"AB0547 ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIES","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Barrie Urology Group","funders":"Sanofi Genzyme; Regeneron Pharmaceuticals; Gilead Sciences; Sanofi; Chugai Pharmaceutical; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Psoriatic arthritis; Internal medicine; Visual analogue scale; Adalimumab; Placebo; Quality of life (healthcare); Clinical trial; Dermatology Life Quality Index; Psoriasis Area and Severity Index; Physical therapy; Psoriasis; Disease; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002116493,0.0004818782,0.001080919,0.0003024868,0.0002746725,0.001018669,0.0003232888,0.0005386175,0.002218586],"category_scores_gemma":[0.00220027,0.0002054703,0.001858399,0.0005293878,0.0002496004,0.0004143657,0.000259935,0.001022683,0.0001765565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003375827,"about_ca_system_score_gemma":0.0004507972,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009235817,"about_ca_topic_score_gemma":0.003075627,"domain_scores_codex":[0.9990066,0.0005027427,0.0001253075,0.0001159062,0.0001299431,0.0001196507],"domain_scores_gemma":[0.9978529,0.0009156973,0.0007148712,0.0001232335,0.0001961273,0.0001971166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4717702,0.001963924,0.3431684,0.00390911,0.02916892,0.0003873784,0.0001624168,0.001746027,0.008519937,0.0007334604,0.008072644,0.1303977],"study_design_scores_gemma":[0.0454538,0.04481958,0.8683954,0.0006017097,0.02228836,0.001160932,0.0002223051,0.001671881,0.003474104,0.0006713808,0.01114047,0.0001001467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9754886,0.01866617,0.0002269619,0.0003862289,0.0001589529,0.0001304946,0.002024732,0.00002301111,0.002894837],"genre_scores_gemma":[0.994862,0.002696363,0.0001556985,0.0002263804,0.00008561144,0.00007464613,0.001432439,0.000004791425,0.0004620155],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002218586,"threshold_uncertainty_score":0.01119316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.067309451921762,"score_gpt":0.383499491645129,"score_spread":0.316190039723367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}